IMEMR
EMRO
66.92
Index Copernicus
ICICICICICICICIC
Volume 4, Issue 2 (2023)
J Clinic Care Skill 2023, 4(2): 63-69 |
Back to browse issues page
Article Type:
History
Received: 2023/04/11 | Accepted: 2023/06/17 | Published: 2023/07/2
Received: 2023/04/11 | Accepted: 2023/06/17 | Published: 2023/07/2
How to cite this article
Hosseini A, Doustimotlagh A H, Afrasiabifar A, Sedaghattalab S. Comparison of Dexamethasone and Hydrocortisone in Management of Exacerbated Chronic Obstructive Pulmonary Disease Patients; a Randomized Controlled Trial. J Clinic Care Skill 2023; 4 (2) :63-69
URL: http://jccs.yums.ac.ir/article-1-185-en.html
URL: http://jccs.yums.ac.ir/article-1-185-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Internal Medicine, Yasuj University of Medical Sciences, Yasuj, Iran
2- Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
3- School of Nursing and Midwifery, Yasuj University of Medical Sciences, Yasuj, Iran
4- Department of Internal Medicine, Yasuj University of Medical Sciences, Yasuj, Iran ,moslem.sedaghattalab@gmail.com
2- Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
3- School of Nursing and Midwifery, Yasuj University of Medical Sciences, Yasuj, Iran
4- Department of Internal Medicine, Yasuj University of Medical Sciences, Yasuj, Iran ,
Abstract (3527 Views)
Aims: Different corticosteroids with different characteristics, such as hydrocortisone and dexamethasone, have been used to treat exacerbated chronic obstructive pulmonary disease, but the drug of choice is unclear. The main goal of the present study was to compare the efficacy of hydrocortisone and dexamethasone on clinical symptoms, peak expiratory flow, oxidative stress factors, and inflammatory mediators in patients with exacerbation of chronic obstructive pulmonary disease.
Materials & Methods: In this single-blind randomized clinical trial study in 2021, 70 eligible patients with chronic obstructive pulmonary disease exacerbations were selected and randomly divided into two A (8mg of intravenous dexamethasone daily) and B (200mg of intravenous daily hydrocortisone) groups. Clinical symptoms and peak expiratory flow were measured before intervention (day 1), after intervention (day 2), and on discharge day. However, oxidative stress factors and inflammatory mediators were evaluated on day one and discharge day. Moreover, the probable complications of both drugs were measured and scaled 1-4 by the researcher.
Findings: Between groups, comparisons showed significant differences in the patients’ clinical indicators for shortness of breath (p=0.02), sputum volume (p=0.01), and oxygen saturation of arterial blood (p=0.02). However, these differences were related to the first day, and no statistically significant differences were observed on the second or discharged days. The intragroup comparison revealed that the prescription of both dexamethasone and hydrocortisone led to significant improvement in the patient’s clinical symptoms.
Conclusion: Dexamethasone and Hydrocortisone are the same in improving important clinical symptoms and have similar efficacy on inflammation and oxidative stress in patients with COPD exacerbation.
Materials & Methods: In this single-blind randomized clinical trial study in 2021, 70 eligible patients with chronic obstructive pulmonary disease exacerbations were selected and randomly divided into two A (8mg of intravenous dexamethasone daily) and B (200mg of intravenous daily hydrocortisone) groups. Clinical symptoms and peak expiratory flow were measured before intervention (day 1), after intervention (day 2), and on discharge day. However, oxidative stress factors and inflammatory mediators were evaluated on day one and discharge day. Moreover, the probable complications of both drugs were measured and scaled 1-4 by the researcher.
Findings: Between groups, comparisons showed significant differences in the patients’ clinical indicators for shortness of breath (p=0.02), sputum volume (p=0.01), and oxygen saturation of arterial blood (p=0.02). However, these differences were related to the first day, and no statistically significant differences were observed on the second or discharged days. The intragroup comparison revealed that the prescription of both dexamethasone and hydrocortisone led to significant improvement in the patient’s clinical symptoms.
Conclusion: Dexamethasone and Hydrocortisone are the same in improving important clinical symptoms and have similar efficacy on inflammation and oxidative stress in patients with COPD exacerbation.
Keywords:
References
1. Vestbo J, Hurd SS, Agust AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(4):347-65. [DOI:10.1164/rccm.201204-0596PP]
2. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: Current burden and future projections. Eur Respir J. 2006;27(2):397‐412 [DOI:10.1183/09031936.06.00025805]
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990‐2020: Global burden of disease study. Lancet. 1997;349(9064):1498‐504. [DOI:10.1016/S0140-6736(96)07492-2]
4. Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: A study of the general population. Am J Respir Crit Care Med. 2012;186:975-981 [DOI:10.1164/rccm.201207-1299OC]
5. Singh JM, Palda VA, Stanbrook MB, Chapman KR. Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: A systematic review. Arch Intern Med. 2002;162(22):2527-36. [DOI:10.1001/archinte.162.22.2527]
6. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847‐52. [DOI:10.1136/thorax.57.10.847]
7. Soler‐Cataluna JJ, Martinnez‐Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925‐31. [DOI:10.1136/thx.2005.040527]
8. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22):2355‐65. [DOI:10.1056/NEJMra0800353]
9. Falk JA, Minai OA, Mosenifar Z. Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):506‐12. [DOI:10.1513/pats.200707-096ET]
10. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173(10):1114‐21. [DOI:10.1164/rccm.200506-859OC]
11. Li H, He G, Chu H, Zhao L, Yu H. A step- wise application of methylprednisolone versus dexamethasone in the treatment of acute exacerbations of COPD. Respirology. 2003;8(2):199-204. [DOI:10.1046/j.1440-1843.2003.00468.x]
12. Wedzicha JA. Oral corticosteroids for exacerbations of chronic obstructive pulmonary disease. Thorax. 2000;55(Suppl 1):S23‐7. [DOI:10.1136/thorax.55.suppl_1.S23]
13. Wood-Baker R, Gibson P, Hannay M, Walters E, Walters J. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Respir Med. 2007;(101):371-7. [DOI:10.1016/j.rmed.2006.07.013]
14. Woods JA, Wheeler JS, Finch CK, Pinner NA. Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014;9:421-30. [DOI:10.2147/COPD.S51012]
15. Walters JA, Gibson PG, Wood-Baker R, Hannay M, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochran Library. 2009;1. [DOI:10.1002/14651858.CD001288.pub3]
16. Abroug F, Ouanes I, Abroug S, Dachraoui F, Abdallah SB, Hammouda Z, et al. Systemic corticosteroids in acute exacerbation of COPD: A meta-analysis of controlled studies with emphasis on ICU patients. Ann Intensive Care. 2014;4(1):32. [DOI:10.1186/s13613-014-0032-x]
17. Koc I, Gogebakan B, Bayraktar R, Tasdemir D, Ozdemir U, Adcock I, et al. Effects of dexamethasone and anti-inflammatory drugs on inflammatory cytokines from bronchial epithelial cells of COPD patients. Eur Respir J. 2015;46:844-9. [DOI:10.1183/13993003.congress-2015.PA884]
18. Sugathan R, Sasikumar S, Alif M. Comparison between hydrocortisone and dexamethasone given intraperitoneally for postoperative pain relief in patients after laparoscopic hysterectomy- an observational study. J Anaesth Pain. 2023;4(1):5-8. [DOI:10.21776/ub.jap.2023.004.01.02]
19. Cevc G, Blume G. Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage. Biochim Biophys Acta. 2004;1663(1-2):61-73. [DOI:10.1016/j.bbamem.2004.01.006]
20. Nebesio TD, Renbarger JL, Nabhan ZM, Ross SE, Slaven JE, Li L, et al. Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: A pilot study in children with congenital adrenal hyperplasia. Int J Pediatr Endocrinol. 2016; 2016:17. [DOI:10.1186/s13633-016-0035-5]
21. Hamzei A, Basiri Mogadam M, Yousefzadeh Ghoochani M, Heidary Karizaki M. Comparison the effects of intravenous hydrocortisone and dexamethasone before extubation on laryngospasm, cough and stridor after general anesthesia. Intern Med Today. 2016;22(2):89-94. [Persian] [DOI:10.18869/acadpub.hms.22.2.89]
22. Marmor M, Jonas A. Corticosteroids for COVID-19- associated ARDS. Clin Pulm Med. 2020;27(6):1. [DOI:10.1097/CPM.0000000000000381]
23. Bullard MJ, Liaw SJ, Tsai YH, Min HP. Early corticosteroid uses in acute exacerbations of chronic airflow obstruction. Am J Emerg Med. 1996;14(2):139-43. [DOI:10.1016/S0735-6757(96)90120-5]
24. Davies L, Angus R, Calverley P. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: A prospective randomised controlled trial. Lancet. 1999;354(9177):456-60. [DOI:10.1016/S0140-6736(98)11326-0]
25. Sharma R, Lettis S, Calverley P, Barnes N. Do inhaled corticosteroids (ICS) reduce rate of decline of lung function in COPD patients with eosinophil count ≥2%. Am J Respir Crit Care Med. 2016;11:2341-8. [link]
26. Magnussen H, Tetzlaff K, Bateman ED, Watz H, Kirsten AM, Wouters EF, et al. Lung-function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD. Eur Respir J. 2016;47(2):651-4. [DOI:10.1183/13993003.01644-2015]
27. Ardestani ME, Kalantary E, Samaiy V, Taherian K. Methyl prednisolone vs dexamethasone in management of COPD exacerbation; A randomized clinical trial. Emerg (Tehran). 2017;5(1):e35. [link]
28. Evensen AE. Management of COPD Exacerbations. Am Fam Physician. 2010;81(5):607-13.
29. Donaldson GC, Seemungal TAR, Hurst JR, Wedzicha JA. Detrended fluctuation analysis of peak expiratory flow and exacerbation frequency in COPD. Eur Respir J. 2012;40:1123-9. [DOI:10.1183/09031936.00180811]
30. Taher A, Lashkari M, Keramat F, Hashemi SH, Sedighi L, Poorolajal J, Mehrpooya M. Comparison of the efficacy of equivalent doses of dexamethasone, methylprednisolone, and hydrocortisone for treatment of COVID-19-related acute respiratory distress syndrome: A prospective three-arm randomized clinical trial. Wien Med Wochenschr. 2023;173:140-51. [DOI:10.1007/s10354-022-00993-4]
31. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693-704. [DOI:10.1056/NEJMoa2021436]
32. Frenkel A, Kachko E, Novack V, Klein M, Brotfain E, Koyfman L, et al. The association of glucocorticosteroid treatment with wbc count in patients with copd exacerbation. J Clin Med. 2019;8(10):1697. [DOI:10.3390/jcm8101697]
33. Pinto-Plata VM, Müllerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006;61(1):23-8. [DOI:10.1136/thx.2005.042200]
34. Lee JS, Shin JH, Hwang JH, Baek JE, Choi BS. Malondialdehyde and 3-nitrotyrosine in exhaled breath condensate in retired elderly coal miners with chronic obstructive pulmonary disease. Saf Health Work. 2014;5(2):91-6. [DOI:10.1016/j.shaw.2014.03.001]
35. Keles MS, Taysi S, Sen N, Aksoy H, Akcay F. Effect of corticosteroid therapy on serum and CSF malondialdehyde and antioxidant proteins in multiple sclerosis. Can J Neurol Sci. 2001;28(2):141-3. [DOI:10.1017/S0317167100052823]
36. Bertram G. Katzung and Trevor's pharmacology examination and board review. 12th ed. New York: McGraw Hill; 2018. [link]
37. Williams DM. Clinical pharmacology of corticosteroids. Respir Care. 2018;63(6):655-70 [DOI:10.4187/respcare.06314]
38. Dernedorf H, Hochhaus G, Barth J, Krieg M, Tunn S, Mollmann H, et al. Receptor based pharmacokinetics- pharmacodynamics analysis of corticosteroids. J Clin Pharmacol. 1993;33(2):115-23. [DOI:10.1002/j.1552-4604.1993.tb03930.x]